Gene Therapy for Hemophilia
Berkeley Pharma Tech Journal of Medicine · 2022
DOI: 10.52243/bptjm.v1i2.28 ↗Kurz gefasst
Fachartikel in der Zeitschrift Berkeley Pharma Tech Journal of Medicine, 2022. Verfasst von Venkata Repaka und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hemophilia is an X-linked recessive genetic disorder in which the body has an inability to clot, leading to increased risk of mortality for individuals if a bleeding episode were to occur. Traditional hemophilia treatments such as prophylactic factor replacement therapy of recombinant factor VIII and IX, have been proven to be costly and do not provide a long-lasting protection during bleeding episodes.(1) In recent years, use of Adeno-associated viral vectors (AAV) gene therapy has been explored as a potential alternative due to efficient gene delivery and tissue tropism, overall safety and efficacy, and longer-lasting effects.(2) However, concerns over inhibitor development still stands as a majorly significant treatment complication that burdens the steady progression of long-term treatment. This review article seeks to provide an overview of the current state of AAV-based gene therapy as a treatment for Hemophilia.
Zitieren
APA
Repaka, V., Lomboy, D., & Castro, P. (2022). Gene Therapy for Hemophilia. Berkeley Pharma Tech Journal of Medicine. https://doi.org/10.52243/bptjm.v1i2.28
Vancouver
Repaka V, Lomboy D, Castro P. Gene Therapy for Hemophilia. Berkeley Pharma Tech Journal of Medicine. 2022. doi:10.52243/bptjm.v1i2.28
BibTeX
@article{Repaka2022,
author = {Repaka, Venkata and Lomboy, Daniel and Castro, Priscilla},
title = {Gene Therapy for Hemophilia},
journal = {Berkeley Pharma Tech Journal of Medicine},
year = {2022},
doi = {10.52243/bptjm.v1i2.28}
}
EUVIMED